NCT06318273 2026-02-09
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
AbbVie
Phase 1 Recruiting
AbbVie
Novartis
Sumitomo Pharma America, Inc.